ChromaDex Corp (CDXC) - Pangali Forward P/E

Concentration risks regarding Tru Niagen and patent costs are weighing on profits, as illustrated by the future P/E multiple for ChromaDex Corporation (CDXC) on GURU.Markets, where the value 38.30 reflects the metric's balance. The business relies on demand within biohacking and dietary supplements, producing NAD+ components, while the scaling of Niagen sales is driven by a strategic partnership with Nestle Health Science.
Rincian metrik lan analitis perusahaan ChromaDex Corporation (CDXC)

The forward P/E ratio for ChromaDex Corporation (CDXC) compares the current market share price with expected net income, determining the extent to which an investor is overpaying for future earnings. The value 38.30 reflects the market's confidence in a stable cash flow from ChromaDex Corporation (CDXC) dietary supplement sales, yet the forward P/E trend allows for an assessment of this valuation's resilience to potential market corrections.